抑制钠-葡萄糖协同转运蛋白2：一种治疗2型糖尿病的新策略。 - Suppr

Suppr

超能文献

Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.

作者信息

Pfister M, Whaley J M, Zhang L, List J F

机构信息

Bristol-Myers Squibb Research and Development, Princeton, New Jersey, USA.

出版信息

Clin Pharmacol Ther. 2011 Apr;89(4):621-5. doi: 10.1038/clpt.2011.16. Epub 2011 Feb 23.

DOI:10.1038/clpt.2011.16

PMID:21346749

Abstract

摘要

相似文献

Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.抑制钠-葡萄糖协同转运蛋白2：一种治疗2型糖尿病的新策略。

Clin Pharmacol Ther. 2011 Apr;89(4):621-5. doi: 10.1038/clpt.2011.16. Epub 2011 Feb 23.

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.钠-葡萄糖协同转运蛋白 2 抑制剂作为抗糖尿病药物的发展历程。

Expert Opin Ther Pat. 2009 Nov;19(11):1485-99. doi: 10.1517/13543770903337828.

Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodium-glucose cotransporter-2 inhibition.科学进步与技术创新的协同作用，通过一种基于机制的模型来描述钠-葡萄糖共转运蛋白 2 抑制作用。

J Clin Pharmacol. 2010 Sep;50(9 Suppl):113S-120S. doi: 10.1177/0091270010376974.

Renal glucose reabsorption inhibitors to treat diabetes.用于治疗糖尿病的肾葡萄糖重吸收抑制剂。

Trends Pharmacol Sci. 2011 Feb;32(2):63-71. doi: 10.1016/j.tips.2010.11.011. Epub 2011 Jan 4.

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白 2 抑制剂：治疗 2 型糖尿病的新兴治疗类别。

J Clin Pharmacol. 2012 Apr;52(4):457-63. doi: 10.1177/0091270011400604. Epub 2011 May 4.

Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.试验观察：SGLT2抑制剂在2型糖尿病治疗中展现出前景。

Nat Rev Drug Discov. 2010 Mar;9(3):182. doi: 10.1038/nrd3127.

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.肾葡萄糖重吸收抑制剂的研发：2型糖尿病药物治疗的新机制

J Med Chem. 2009 Apr 9;52(7):1785-94. doi: 10.1021/jm8013019.

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.发现坎格列净，一种新型含噻吩环的 C-糖苷，作为钠依赖性葡萄糖共转运蛋白 2 抑制剂用于治疗 2 型糖尿病。

J Med Chem. 2010 Sep 9;53(17):6355-60. doi: 10.1021/jm100332n.

Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.新型L-木糖衍生物作为选择性钠依赖性葡萄糖协同转运蛋白2（SGLT2）抑制剂用于治疗2型糖尿病。

J Med Chem. 2009 Oct 22;52(20):6201-4. doi: 10.1021/jm900951n.

Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂：新型抗糖尿病药物。

Expert Opin Ther Pat. 2012 May;22(5):483-94. doi: 10.1517/13543776.2012.680437.

引用本文的文献

Sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病中的安全性取决于其药物不良反应和血糖监测参数。

Indian J Pharmacol. 2025 Sep 1;57(5):329-333. doi: 10.4103/ijp.ijp_924_24. Epub 2025 Aug 22.

Management of diabesity: Current concepts.糖尿病肥胖症的管理：当前概念

World J Diabetes. 2023 Apr 15;14(4):396-411. doi: 10.4239/wjd.v14.i4.396.

Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia.基于足细胞尿的 SGLT2 抑制剂对糖尿病肾病患者的影响：一项初步研究。

J Diabetes. 2022 Apr;14(4):236-246. doi: 10.1111/1753-0407.13261. Epub 2022 Feb 28.

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.SGLT-2 抑制剂在伴有或不伴有 2 型糖尿病的患者中的心血管和肾脏结局：11 项心血管结局试验的荟萃分析。

Cardiovasc Diabetol. 2021 Dec 16;20(1):236. doi: 10.1186/s12933-021-01430-3.

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.达格列净对伴或不伴糖尿病的心力衰竭患者心力衰竭恶化和心血管死亡的影响。

JAMA. 2020 Apr 14;323(14):1353-1368. doi: 10.1001/jama.2020.1906.

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats.恩格列净可减轻链脲佐菌素诱导的糖尿病大鼠心肌钠钙失调并逆转心脏重构。

Int J Mol Sci. 2019 Apr 4;20(7):1680. doi: 10.3390/ijms20071680.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：一类不断发展的抗糖尿病药物。

Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014.

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans.利用系统药理学模型阐明 SGLT1 和 SGLT2 在人体肾葡萄糖重吸收中的作用特征。

Front Pharmacol. 2014 Dec 10;5:274. doi: 10.3389/fphar.2014.00274. eCollection 2014.

Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy.在糖尿病肾病早期，高血糖通过SGLT2和p21依赖性途径导致近端肾小管细胞衰老。

J Diabetes Complications. 2014 Sep-Oct;28(5):604-11. doi: 10.1016/j.jdiacomp.2014.05.010. Epub 2014 Jun 4.

Chances and risks of SGLT2 inhibitors.钠-葡萄糖协同转运蛋白2抑制剂的机遇与风险。

Naunyn Schmiedebergs Arch Pharmacol. 2012 Jun;385(6):551-4. doi: 10.1007/s00210-011-0720-0. Epub 2011 Dec 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验